We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial.
Gilead Sciences announced STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1).....